Literature DB >> 12759363

DEN1 is a dual function protease capable of processing the C terminus of Nedd8 and deconjugating hyper-neddylated CUL1.

Kenneth Wu1, Kosj Yamoah, Georgia Dolios, Tudeviin Gan-Erdene, Peilin Tan, Angus Chen, Chee-Gun Lee, Ning Wei, Keith D Wilkinson, Rong Wang, Zhen-Qiang Pan.   

Abstract

Nedd8 activates ubiquitination by increasing the efficiency of polyubiquitin chain assembly through its covalent conjugation to cullin molecules. Here we report the isolation, cloning, and characterization of a novel human Nedd8-specific protease called DEN1. Human DEN1 is encoded by AAH31411.1, a previously uncharacterized protein of 212 amino acids that shares homology with the Ulp1 cysteinyl SUMO deconjugating enzyme family. Recombinant human DEN1, purified from bacteria, selectively binds to Nedd8 and hydrolyzes C-terminal derivatives of Nedd8. Interestingly, DEN1 deconjugates cullin 1 (CUL1)-Nedd8 in a concentration-dependent manner. At a low concentration, DEN1 processes hyper-neddylated CUL1 to yield a mononeddylated form, which presumably contains the Lys-720CUL1-Nedd8 linkage. At elevated concentrations, DEN1 is able to complete the removal of Nedd8 from CUL1. These activities distinguish DEN1 from the COP9 signalosome, which is capable of efficiently cleaving the Lys-720CUL1-Nedd8 conjugate, but lacks Nedd8 C-terminal hydrolytic activity and poorly processes hyperneddylated CUL1. These results suggest a unique role for DEN1 in regulating the modification of cullins by Nedd8.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759363     DOI: 10.1074/jbc.M302888200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  74 in total

Review 1.  Adenosine and hypoxia-inducible factor signaling in intestinal injury and recovery.

Authors:  Sean P Colgan; Holger K Eltzschig
Journal:  Annu Rev Physiol       Date:  2011-11-19       Impact factor: 19.318

Review 2.  The devil is in the details: comparison between COP9 signalosome (CSN) and the LID of the 26S proteasome.

Authors:  Cindy Meister; Miriam Kolog Gulko; Anna M Köhler; Gerhard H Braus
Journal:  Curr Genet       Date:  2016-02       Impact factor: 3.886

3.  SCFFBXO22 targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis.

Authors:  Jin Bai; Kenneth Wu; Meng-Han Cao; Yingying Yang; Yu Pan; Hui Liu; Yizhou He; Yoko Itahana; Lan Huang; Jun-Nian Zheng; Zhen-Qiang Pan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-28       Impact factor: 11.205

4.  The SUMO-specific protease SENP5 is required for cell division.

Authors:  Alessandra Di Bacco; Jian Ouyang; Hsiang-Ying Lee; Andre Catic; Hidde Ploegh; Grace Gill
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

Review 5.  Dissecting the ubiquitin pathway by mass spectrometry.

Authors:  Ping Xu; Junmin Peng
Journal:  Biochim Biophys Acta       Date:  2006-09-14

Review 6.  Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes.

Authors:  Francisca E Reyes-Turcu; Karen H Ventii; Keith D Wilkinson
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

7.  Mono-ubiquitination drives nuclear export of the human DCN1-like protein hDCNL1.

Authors:  Kenneth Wu; Hua Yan; Lei Fang; Xinjiang Wang; Cathie Pfleger; Xuejun Jiang; Lan Huang; Zhen-Qiang Pan
Journal:  J Biol Chem       Date:  2011-08-03       Impact factor: 5.157

Review 8.  The enzymes in ubiquitin-like post-translational modifications.

Authors:  Yuan Chen
Journal:  Biosci Trends       Date:  2007-08       Impact factor: 2.400

Review 9.  Function and regulation of protein neddylation. 'Protein modifications: beyond the usual suspects' review series.

Authors:  Gwénaël Rabut; Matthias Peter
Journal:  EMBO Rep       Date:  2008-09-19       Impact factor: 8.807

10.  Characterization of the human COP9 signalosome complex using affinity purification and mass spectrometry.

Authors:  Lei Fang; Xiaorong Wang; Kosj Yamoah; Phang-lang Chen; Zhen-Qiang Pan; Lan Huang
Journal:  J Proteome Res       Date:  2008-10-14       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.